Bio Green Med Solution, Inc. (BGMS) presents a marginally positive but structurally precarious liquidation posture as of March 31, 2026. The entity underwent a complete business transformation: formerly Cyclacel Pharmaceuticals, it exited biopharmaceuticals via the voluntary liquidation of UK subsidiary Cyclacel Limited in January 2025 and the sale of the Plogosertib asset in October 2025, and pivoted to fire safety equipment distribution through the September 2025 acquisition of Malaysia-based Fitters Sdn. Bhd. The prior 10-K (year ended December 31, 2025) serves as the comparison base. Reported stockholders' equity as of March 31, 2026 is $6.76 million, down from $6.84 million at December 31, 2025, driven by a $197K net loss, $20K preferred dividend payment, and a $9K favorable FX translation, partially offset by $126K in warrant exchange proceeds and stock comp. Accumulated deficit stands at $454.6 million. Under liquidation haircuts applied to the MFFAIS-provided values, the Company's liquidation profile is as follows: cash of approximately $3.34 million recovers at 100%; accounts receivable net of $1.19 million recovers at 90-95% (approximately $1.07-1.13 million), though gross AR of $1.47 million carries a $286K allowance for doubtful accounts already reflected; inventory of $947K recovers at approximately 60% ($568K) — the business is a distributor of tangible fire safety products so liquidation realizations could be lower for specialty items; non-current assets of approximately $200K represent an 8% interest-bearing loan to an unrelated Malaysian customer, recovery uncertain; PP&E is de minimis based on depreciation of $1K/quarter. Total liquid asset recovery approximates $5.0-5.2 million. Against this, current liabilities of $796K (accrued legal/professional fees $446K, other current liabilities $94K, operating lease obligations $11K, and accounts payable) settle at face value. The operating lease remaining obligation is only $11K total across two tranches ($9K 2026, $2K 2027), not a material liability. There are no long-term debt obligations disclosed. The Series A Preferred Stock (264 shares outstanding, $1,000 liquidation preference per share, total $264K face) ranks senior to common in liquidation. The 6% Convertible Exchangeable Preferred Stock (135,273 shares at $10/share liquidation preference = $1.35 million) also ranks senior. Aggregate preferred liquidation stack is approximately $1.62 million. Net recovery to common equity on liquidation is therefore approximately $5.0-5.2M (assets) minus $796K (current liabilities) minus $1.62M (preferred stack) = approximately $2.6-2.8M. The MFFAIS CLV of $2.15 million is directionally consistent with this estimate, reflecting the subordination to preferred and haircuts on illiquid assets. Going concern disclosure is explicit: management states cash of $3.3M will sustain operations only into Q4 2026, with substantial doubt about continuity beyond 12 months. The filing does not separately tag balance sheet line items in XBRL; all TAG_CONTEXT is empty. Key balance sheet and cash flow figures referenced above are drawn from narrative and inline XBRL fact instances in the filing body. Filing discusses the non-current customer loan ($0.4M MYR 1.7M equivalent) and allowance for doubtful accounts methodology in MD&A and notes but does not emit separate XBRL tags for these items in the TAG_CONTEXT provided.
▼ Community Notes